Pooled Analysis of Combination Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting in Patients with Colorectal Cancer Treated with Oxaliplatin-based Chemotherapy of Moderate Emetic Risk

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Oct 17

PMID 34656107

Citations 2

Authors

Mototsugu Shimokawa

Toshinobu Hayashi

Junichi Nishimura

Taroh Satoh

Mutsumi Fukunaga

Reiko Matsui

Yasushi Tsuji

Fumitaka Mizuki

Takahiro Kogawa

Affiliations

Soon will be listed here.

Abstract

Background: Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled.

Methods: We pooled data from two prospective observational studies in Japan and one phase III clinical trial to assess whether delayed CINV could be controlled with a combination of three antiemetics adding a neurokinin-1 receptor antagonist and identified individual risk factors, using an inverse probability treatment-weighted analysis.

Results: A total of 661 patients were evaluable in this study (median age: 64 years; 391 male, and 270 female). 3 antiemetics controlled delayed nausea (33.18% vs. 42.25%; p = 0.0510) and vomiting (4.15% vs. 16.08%; p < 0.0001) better than with 2 antiemetics. Female and 2 antiemetics were risk factors for both delayed nausea (female-odds ratio [OR]: 1.918; 95% confidence interval [CI]: 1.292-2.848; p = 0.0012; 2 antiemetics-OR: 1.485; 95% CI: 1.000-2.204; p = 0.0498) and delayed vomiting (female-OR: 2.735; 95% CI: 1.410-5.304; p = 0.0029; 2 antiemetics-OR: 4.551; 95% CI: 2.116-9.785; p = 0.0001).

Conclusions: Identifying individual risk factors can facilitate personalized treatments for delayed CINV. We recommend a 3-antiemetic combination prophylaxis for CRC patients treated with L-OHP-based chemotherapy, especially for female patients.

Citing Articles

The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.

Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M Curr Med Chem. 2023; 31(39):6487-6509.

PMID: 37861026 DOI: 10.2174/0109298673261625230924114406.

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy.

Shimokawa M, Haratake N, Takada K, Toyokawa G, Takamori S, Mizuki F Cancer Manag Res. 2022; 14:2673-2680.

PMID: 36110158 PMC: 9470117. DOI: 10.2147/CMAR.S370961.

References

Roscoe J, Bushunow P, Morrow G, Hickok J, Kuebler P, Jacobs A . Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer. 2004; 101(11):2701-8. DOI: 10.1002/cncr.20718. View

Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M . Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 1991; 14(3):238-42. DOI: 10.1097/00000421-199106000-00010. View

Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J . A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer. 2017; 25(9):2707-2714. DOI: 10.1007/s00520-017-3679-7. View

Hesketh P, Sanz-Altamira P, Bushey J, Hesketh A . Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer. 2011; 20(5):1043-7. DOI: 10.1007/s00520-011-1180-2. View

Herrstedt J . Nausea and emesis: still an unsolved problem in cancer patients?. Support Care Cancer. 2002; 10(2):85-7. DOI: 10.1007/s00520-001-0339-7. View

Roila F, Warr D, Hesketh P, Gralla R, Herrstedt J, Jordan K . 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2016; 25(1):289-294. DOI: 10.1007/s00520-016-3365-1. View

Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J . Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer. 1994; 2(3):161-6. DOI: 10.1007/BF00417474. View

Iihara H, Ishihara M, Fujii H, Yoshimi C, Yamada M, Suzuki A . Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens. J Cancer. 2016; 7(5):569-75. PMC: 4820733. DOI: 10.7150/jca.13637. View

Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L . Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997; 15(1):116-23. DOI: 10.1200/JCO.1997.15.1.116. View

10.

Bois A, Meerpohl H, Vach W, Kommoss F, Fenzl E, Pfleiderer A . Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992; 28(2-3):450-7. DOI: 10.1016/s0959-8049(05)80075-9. View

11.

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa S, Isambert N . Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2013; 47(5):839-848.e4. DOI: 10.1016/j.jpainsymman.2013.06.012. View

12.

Wood D, Kazerooni E, Baum S, Eapen G, Ettinger D, Hou L . Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(4):412-441. PMC: 6476336. DOI: 10.6004/jnccn.2018.0020. View

13.

Sekine I, Segawa Y, Kubota K, Saeki T . Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013; 104(6):711-7. PMC: 7657206. DOI: 10.1111/cas.12146. View

14.

Wang D, Hu M, Wang Z, Ren C, Qiu M, Luo H . Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open. 2021; 4(4):e215250. PMC: 8035650. DOI: 10.1001/jamanetworkopen.2021.5250. View

15.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

16.

Goldberg R, Sargent D, Morton R, Fuchs C, Ramanathan R, Williamson S . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2003; 22(1):23-30. DOI: 10.1200/JCO.2004.09.046. View

17.

Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T . 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. BMC Pharmacol Toxicol. 2020; 21(1):72. PMC: 7539512. DOI: 10.1186/s40360-020-00445-y. View

18.

Takemoto H, Nishimura J, Komori T, Kim H, Ota H, Suzuki R . Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol. 2016; 22(1):88-95. DOI: 10.1007/s10147-016-1022-9. View

19.

Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26(12):2006-12. DOI: 10.1200/JCO.2007.14.9898. View

20.

Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y . Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015; 51(10):1274-82. DOI: 10.1016/j.ejca.2015.03.024. View